Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

An experimental DNA vaccine against multiple sclerosis (MS) appears safe in early human tests and shows signs of effectiveness, according to a paper published Monday in the online version of the Archives of Neurology.

In MS, the immune system attacks the fatty coating, known as myelin, protecting nerve cells in the brain and spinal cord, eventually destroying nerve cells’ ability to communicate. The cause of the disease is unknown.

In the study, headed by Amit Bar-Or of the Montreal Neurological Institute in Canada, patients were given a vaccine made up of one of the protein components of myelin. The idea is that the vaccine will damp the body’s tendency to attack myelin.

While larger studies are needed to determine if the vaccine will truly help MS patients, initial results were promising. The vaccine appears safe and showed early signs of a beneficial effect on the immune system: the number of immune cells in the spinal fluid that attack myelin was reduced in a small subset of patients who underwent lumbar puncture. A larger study of the vaccine is now under way.

0 comments about this story. Start the discussion »

Tagged: Biomedicine, vaccine, virus protection

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me